Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy

• Published in: Natural product reports Vol. 38; no. 3; pp. 47 - 488
• Main Authors: Zhao, Wei, Cong, Ying, Li, Hong-Mei, Li, Shengying, Shen, Yuemao, Qi, Qingsheng, Zhang, Youming, Li, Yue-Zhong, Tang, Ya-Jie
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 01.03.2021
• Subjects: Anticancer properties; antineoplastic activity; Antineoplastic Agents - therapeutic use; Antitumor activity; bioactive compounds; Bioavailability; Biocompatibility; Cancer therapies; cancer therapy; Cell cycle; Central nervous system; Chemotherapy; Coronaviruses; COVID-19; COVID-19 infection; Cytokine storm; Cytokines; Deoxyribonucleic acid; DNA; DNA damage; DNA topoisomerase (ATP-hydrolysing); Drug Design; Drug development; Drug resistance; drug therapy; Drugs; Etoposide; Growth factors; Health services; Herbal medicine; herbal medicines; Humans; Insulin; insulin-like growth factor I receptor; Lung cancer; lung neoplasms; Neoplasms - drug therapy; Podophyllotoxin; Podophyllotoxin - therapeutic use; Podophyllum; RNA; Small cell lung carcinoma; Teniposide; testes; Testicular cancer; Toxicity; Tubulin; Viral diseases

Covering: up to 2020 As a main bioactive component of the Chinese, Indian, and American Podophyllum species, the herbal medicine, podophyllotoxin (PTOX) exhibits broad spectrum pharmacological activity, such as superior antitumor activity and against multiple viruses. PTOX derivatives (PTOXs) could...